Clinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: A case series

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Rasmussen, Anne ^a   Jørgensen, Niklas ^a   Schwarz, Peter ^a,b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CINACALCET; MAGNESIUM; PARATHYROID HORMONE;

ADULT; ARTICLE; BIOCHEMISTRY; BONE MASS; CALCIUM BLOOD LEVEL; CASE REPORT; CASR GENE; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFECT; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPERCALCEMIA; LABORATORY TEST; MAGNESIUM BLOOD LEVEL; PARATHYROID HORMONE BLOOD LEVEL; PEDIGREE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 82655189396     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-564     Document Type: Article

References (15)

1. Inter-relations between the calcium set-points of Parfitt and Brown in primary hyperparathyroidism: a sequential citrate and calcium clamp study. Schwarz P, Sorensen HA, Transbol I, Eur J Clin Invest 1994 24 553 558 10.1111/j.1365-2362.1994.tb01106.x 7982443 (Pubitemid 24251583)
2. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Brown EM, Endocrinol Metab Clin North Am 2000 29 503 522 10.1016/S0889-8529(05)70148-1 11033758
3. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR). Brown EM, Biochem Pharmacol 2010 80 297 307 10.1016/j.bcp.2010.04.002 20382129
4. Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants. White E, McKenna J, Cavanaugh A, Breitwieser GE, Mol Endocrinol 2009 23 1115 1123 10.1210/me.2009-0041 19389809
5. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D, J Clin Endocrinol Metab 2011 96 9 E18 10.1210/jc.2010-1221 20943783
6. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M, J Clin Endocrinol Metab 2003 88 5644 5649 10.1210/jc.2002-021597 14671147 (Pubitemid 38033028)
7. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM, Nephrol Dial Transplant 2005 20 2186 2193 10.1093/ndt/gfh966 16030053 (Pubitemid 41510096)
8. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP, J Clin Endocrinol Metab 2007 92 3803 3808 10.1210/jc.2007-0585 17666472 (Pubitemid 47607626)
9. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D, J Clin Endocrinol Metab 2009 94 4860 4867 10.1210/jc.2009-1472 19837909
10. Management of skeletal health in patients with asymptomatic primary hyperparathyroidism. Lewiecki EM, J Clin Densitom 2010 13 324 334 10.1016/j.jocd.2010.06.004 21029971
11. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. Timmers HJ, Karperien M, Hamdy NA, de BH, Hermus AR, J Intern Med 2006 260 177 182 10.1111/j.1365-2796.2006.01684.x 16882283 (Pubitemid 44051343)
12. Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia. Festen-Spanjer B, Haring CM, Koster JB, Mudde AH, Clin Endocrinol (Oxf) 2008 68 324 325
13. Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Alon US, Vandevoorde RG, Pediatr Nephrol 2010 25 1747 1750 10.1007/s00467-010-1547-5 20495831
14. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. Reh CM, Hendy GN, Cole DE, Jeandron DD, J Clin Endocrinol Metab 2011 96 707 12 10.1210/jc.2010-1306 21289269
15. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism associated with mutations in the human Ca2+-sensing receptor gene in three Danish families. Schwarz P, Larsen NE, Lonborg Friis IM, Lillquist K, Brown EM, Gammeltoft S, Scand J Clin Lab Invest 2000 60 221 227 10.1080/003655100750044875 10885494